Editas Medicine Return on Equity (ROE) Growth & History (EDIT)

Editas Medicine's return on equity was −198.14% for fiscal 2025.

View full Editas Medicine company overview

Editas Medicine annual return on equity history

Editas Medicine annual return on equity

Fiscal yearPeriod endedReturn on equityChange (percentage points)
20252025-12-31−198.14%−100.04 pp
20242024-12-31−98.10%−54.93 pp
20232023-12-31−43.17%+5.04 pp
20222022-12-31−48.22%−7.57 pp
20212021-12-31−40.65%−5.29 pp
20202020-12-31−35.36%+18.29 pp
20192019-12-31−53.65%−4.15 pp
20182018-12-31−49.50%+20.72 pp
20172017-12-31−70.22%+307.24 pp
20162016-12-31−377.46%

Editas Medicine return on equity trends

Over the last five fiscal years, Editas Medicine's return on equity decreased from −35.36% to −198.14%, a change of −162.78 percentage points. The latest reported quarter, Q2 2026, shows −33.24%.

About the metric

What return on equity (ROE) means

Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.

Calculation and source

How return on equity is calculated

TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.

Review Editas Medicine source filings ↗

Community posts

It’s quiet here.

No posts about EDIT yet. Start the conversation.

Write the first post